Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.

ABSTRACT:

Background

Typhoid fever is a major public health problem in low-resource settings. Vaccination can help curb the disease and might reduce transmission. We have previously reported an interim analysis of the efficacy of typhoid conjugate vaccine (TCV) in Nepali children. Here we report the final results after 2 years of follow-up.

Methods

We did a participant-masked and observer-masked individually randomised trial in Lalitpur, Nepal, in which 20 019 children aged 9 months to younger than 16 years were randomly assigned in a 1:1 ratio to receive a single dose of TCV (Typbar TCV, Bharat Biotech International, India) or capsular group A meningococcal conjugate vaccine (MenA). Participants were followed up until April 9, 2020. The primary outcome was blood culture-confirmed typ

SUBMITTER: Shakya M 

PROVIDER: S-EPMC8551681 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature